<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Liver_Cirrhosis.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:30:41 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="1231004">
<meta name="Category" content="Concern">
<meta name="Article" content="Liver_Cirrhosis">
<title>Cirrosis Hep&#225;tica-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">Cirrosis Hep&#225;tica</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="Liver_Cirrhosis.htm">Volver al
art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Beers MH, Berkow R (eds). <em>The Merck Manual,</em> 17th ed. Whitehouse
Station, NJ: Merck and Co., Inc., 1999, 372&#8211;4.</li>

<li class="Ref">Lochs H, Plauth M. Liver cirrhosis: rationale and modalities for nutritional
support&#8212;the European Society of Parenteral and Enteral Nutrition consensus and beyond.
<em>Curr Opin Clin Nutr Metab Care</em> 1999;2:345&#8211;9.</li>

<li class="Ref">Lieber CS. Nutrition in liver disorders. In: Shils ME, Olson JA, Shike M, Ross
AC (eds). <em>Modern Nutrition in Health and Disease,</em> 9th ed. Baltimore, MD: Williams and
Wilkins, 1999, 1179&#8211;80.</li>

<li class="Ref">Rodriguez-Moreno F, Gonzalez-Reimers E, Santolaria-Fernandez F, et al. Zinc,
copper, manganese, and iron in chronic alcoholic liver disease. <em>Alcohol</em>
1997;14:39&#8211;44.</li>

<li class="Ref">Gibbs K, Walshe JM. Studies with radioactive copper (64 Cu and 67 Cu); the
incorporation of radioactive copper into caeruloplasmin in Wilson&#8217;s disease and in
primary biliary cirrhosis. <em>Clin Sci</em> 1971;41:189&#8211;202.</li>

<li class="Ref">Lieber CS. Nutrition in liver disorders. In: Shils ME, Olson JA, Shike M, Ross
AC (eds). <em>Modern Nutrition in Health and Disease,</em> 9th ed. Baltimore, MD: Williams and
Wilkins, 1999:1179&#8211;80.</li>

<li class="Ref">Halsted CH. Alcohol: medical and nutritional effects. In Ziegler EE, Filer LJ
(eds). <em>Present Knowledge in Nutrition,</em> 7th ed. ILSI Press, Washington, DC, 1996,
553.</li>

<li class="Ref">Roggin GM, Iber FL, Kater RM, Tabon F. Malabsorption in the chronic alcoholic.
<em>Johns Hopkins Med J</em> 1969;125:321&#8211;30.</li>

<li class="Ref">Roggin GM, Iber FL, Linscheer WG. Intraluminal fat digestion in the chronic
alcoholic. <em>Gut</em> 1972;13:107&#8211;11.</li>

<li class="Ref">Luca A, Garcia-Pagan JC, Bosch J, et al. Effects of ethanol consumption on
hepatic hemodynamics in patients with alcoholic cirrhosis. <em>Gastroenterology</em>
1997;112:1284&#8211;9.</li>

<li class="Ref">Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in
alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter
clinical trial. <em>J Hepatol</em> 1999;30:1081&#8211;9.</li>

<li class="Ref">Miglio F, Stefanini GF, Corazza GR, et al. Double-blind studies of the
therapeutic action of S-Adenosylmethionine (SAMe) in oral administration, in liver cirrhosis
and other chronic hepatitides. <em>Minerva Med</em> 1975;66:1595&#8211;9 [In Italian].</li>

<li class="Ref">Gorbakov VV, Galik VP, Kirillov SM. Experience in heptral treatment of diffuse
liver diseases. <em>Ter Arkh</em> 1998;70:82&#8211;6 [in Russian].</li>

<li class="Ref">Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L-methionine
administration on red blood cell cysteine and glutathione levels in alcoholic patients with
and without liver disease. <em>Alcohol Alcohol</em> 1994;29:597&#8211;604.</li>

<li class="Ref">Frezza M, Centini G, Cammareri G, et al. S-adenosylmethionine for the
treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial.
<em>Hepatogastroenterology</em> 1990;37 Suppl 2:122&#8211;5.</li>

<li class="Ref">Frezza M, Surrenti C, Manzillo G, et al. Oral S-adenosylmethionine in the
symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study.
<em>Gastroenterology</em> 1990;99:211&#8211;5.</li>

<li class="Ref">Lieber CS. Nutrition in liver disorders. In: Shils ME, Olson JA, Shike M, Ross
AC (eds). <em>Modern Nutrition in Health and Disease,</em> 9th ed. Baltimore, MD: Williams and
Wilkins, 1999, 1179&#8211;80.</li>

<li class="Ref">Beers MH, Berkow R (eds). <em>The Merck Manual</em>, 17th ed. Whitehouse
Station, NJ: Merck and Co., Inc., 1999, 362&#8211;4.</li>

<li class="Ref">Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver
disease: an analytical review. <em>Hepatology</em> 1994;19:518&#8211;33 [review].</li>

<li class="Ref">Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral,
branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a
randomized controlled trial. <em>Hepatology</em> 1984;4:279&#8211;87.</li>

<li class="Ref">Okita M, Watanabe A, Nagashima H. Treatment of liver cirrhosis with branched
chain amino acid-supplemented diet. <em>Gastroenterol Jpn</em> 1981;16:389&#8211;92.</li>

<li class="Ref">Maddrey WC. Branched chain amino acid therapy in liver disease. <em>J Am Coll
Nutr</em> 1985;4:639&#8211;50 [review].</li>

<li class="Ref">Wahren J, Denis J, Desurmont P, et al. Is intravenous administration of
branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter
study. <em>Hepatology</em> 1983;3(4):475&#8211;80.</li>

<li class="Ref">Egberts E-H, Schomerus H, Hamster W, J&#252;rgens P. Branched chain amino
acids in the treatment of latent portosystemic encephalopathy. <em>Gastroenterol</em>
1985;88:887&#8211;95.</li>

<li class="Ref">Dioguardi FS, Brigatti M, Dell&#8217;Oca M, et al. Effects of chronic oral
branched-chain amino acid supplementation in a subpopulation of cirrhotics. <em>Clin Physiol
Biochem</em> 1990;8:101&#8211;7.</li>

<li class="Ref">Marchesini G, Dioguardi FS, Bianchi GP, et al. Long-term oral branched-chain
amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind
casein-controlled trial. The Italian Multicenter Study Group. <em>J Hepatol</em>
1990;11:92&#8211;101.</li>

<li class="Ref">Chin SE, Shepherd RW, Thomas BJ, et al. Nutritional support in children with
end-stage liver disease: a randomized crossover trial of a branched-chain amino acid
supplement. <em>Am J Clin Nutr</em> 1992;56:158&#8211;63.</li>

<li class="Ref">Kato M, Miwa Y, Tajika M, et al. Preferential use of branched-chain amino
acids as an energy substrate in patients with liver cirrhosis. <em>Internal Med</em>
1998;37:429&#8211;34.</li>

<li class="Ref">Ma X, Zhao J, Lieber CS. Polyenylphosphatidylcholine attenuates non-alcoholic
hepatic fibrosis and accelerates its regression. <em>J Hepatol</em> 1996;24:604&#8211;13.</li>

<li class="Ref">Lieber CS, Robins SJ, Leo MA. Hepatic phosphatidylethanolamine
methyltransferase activity is decreased by ethanol and increased by phosphatidylcholine. <em>
Alcohol Clin Exp Res</em> 1994;18:592&#8211;5.</li>

<li class="Ref">Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against
fibrosis and cirrhosis in the baboon. <em>Gastroenterology</em> 1994;106:152&#8211;9.</li>

<li class="Ref">Lieber CS, DeCarli LM, Mak KM, et al. Attenuation of alcohol-induced hepatic
fibrosis by polyunsaturated lecithin. <em>Hepatology</em> 1990;12:1390&#8211;8.</li>

<li class="Ref">Fassati P, Horejsi J, Fassati M, et al. Essential choline phospholipids and
their effect on HBsAg and selected biochemical tests in cirrhosis of the liver. <em>Cas Lek
Cesk</em> 1981 22;120:56&#8211;60 [in Czech].</li>

<li class="Ref">Taniguchi S, Kaneto K, Hamada T. Acquired zinc deficiency associated with
alcoholic liver cirrhosis. <em>Int J Dermatol</em> 1995;34:651&#8211;2.</li>

<li class="Ref">Scholmerich J, Lohle E, Kottgen E, Gerok W. Zinc and vitamin A deficiency in
liver cirrhosis. <em>Hepatogastroenterology</em> 1983;30:119&#8211;25.</li>

<li class="Ref">Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic
encephalopathy. Results of a randomised controlled trial. <em>Lancet</em>
1984;2(8401):493&#8211;5.</li>

<li class="Ref">Marchesini G, Fabbri A, Bianchi G, et al. Zinc supplementation and amino
acid-nitrogen metabolism in patients with advanced cirrhosis. <em>Hepatology</em>
1996;23:1084&#8211;92.</li>

<li class="Ref">Sturniolo GC, D&#8217;Inca R, Parisi G, et al. Taste alterations in liver
cirrhosis: are they related to zinc deficiency? <em>J Trace Elem Electrolytes Health Dis</em>
1992;6:15&#8211;9.</li>

<li class="Ref">Weismann K, Christensen E, Dreyer V. Zinc supplementation in alcoholic
cirrhosis. A double-blind clinical trial. <em>Acta Med Scand</em>
1979;205(5):361&#8211;6.</li>

<li class="Ref">Vlahcevic ZR, Miller JR, Farrar JT, Swell L. Kinetics and pool size of primary
bile acids in man. <em>Gastroenterology</em> 1971;61:85&#8211;90.</li>

<li class="Ref">Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays
histological progression in primary biliary cirrhosis. <em>Hepatology</em>
1999;29:644&#8211;7.</li>

<li class="Ref">Larghi A, Crosignani A, Battezzati PM, et al. Ursodeoxycholic and
tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover
study. <em>Aliment Pharmacol Ther</em>. 1997;11:409&#8211;14.</li>

<li class="Ref">Crosignani A, Battezzati PM, Setchell KD, et al. Tauroursodeoxycholic acid for
treatment of primary biliary cirrhosis. A dose-response study. <em>Dig Dis Sci</em>
1996;41:809&#8211;15.</li>

<li class="Ref">Setchell KD, Rodrigues CM, Podda M, Crosignani A. Metabolism of orally
administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. <em>
Gut</em> 1996;38:439&#8211;46.</li>

<li class="Ref">Ferri F, Bernocchi P, Fedeli S. Taurodeoxycholic acid in the treatment of
primary biliary cirrhosis. A controlled study in comparison to ursodeoxycholic acid. <em>Clin
Ter</em> 1993;143:321&#8211;6 [in Italian].</li>

<li class="Ref">Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic
acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial.
UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. <em>J
Hepatol</em> 2000;32:561&#8211;6.</li>

<li class="Ref">Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of
chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. <em>J
Hepatol</em> 1998;28:856&#8211;64.</li>

<li class="Ref">Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of
L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy:
results of a placebo-controlled, double-blind study. <em>Hepatology</em>
1997;25:1351&#8211;60.</li>

<li class="Ref">Staedt U, Leweling H, Gladisch R, et al. Effects of ornithine aspartate on
plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized
study using a four-fold crossover design. <em>J Hepatol</em> 1993;19:424&#8211;30.</li>

<li class="Ref">Pugliese D, Sabba C, Ettorre G et al. Acute systemic and splanchnic
haemodynamic effects of l-carnitine in patients with cirrhosis. <em>Drugs Exp Clin Res</em>
1992;18:147&#8211;53.</li>

<li class="Ref">Ferro D, Basili S, Practico D, et al. Vitamin E reduces monocyte tissue factor
expression in cirrhotic patients. <em>Blood</em> 1999;93:2945&#8211;50.</li>

<li class="Ref">de la Maza MP, Petermann M, Bunout D, Hirsch S. Effects of long-term vitamin E
supplementation in alcoholic cirrhotics. <em>J Am Coll Nutr</em> 1995;14:192&#8211;6.</li>

<li class="Ref">Burk RF, Early DS, Hill KE, et al. Plasma selenium in patients with cirrhosis.
<em>Hepatology</em> 1998;27:794&#8211;8.</li>

<li class="Ref">Feher J, Lengyel G, Blazovics A. Oxidative stress in the liver and biliary
tract diseases. <em>Scand J Gastroenterol Suppl</em> 1998;228:38&#8211;46.</li>

<li class="Ref">Van Gossum A, Neve J. Low selenium status in alcoholic cirrhosis is correlated
with aminopyrine breath test. Preliminary effects of selenium supplementation. <em>Biol Trace
Elem Res</em> 1995;47:201&#8211;7.</li>

<li class="Ref">Shiomi S, Masaki K, Habu D, et al. Calcitriol for bone loss in patients with
primary biliary cirrhosis. <em>J Gastroenterol</em> 1999;34:241&#8211;5.</li>

<li class="Ref">Yamamoto M, Oka H, Kanno T, et al. Controlled prospective trial to evaluate
sho-saiko-to for the prevention of hepatotcellular carcinoma in patients with cirrhosis of the
liver. <em>Gan To Kagaku Ryoho</em> (<em>Jpn J Cancer Chemother)</em> 1989;16:1519&#8211;24
[in Japanese].</li>

<li class="Ref">Kumada T, et al. Effect of shakuyaku-kanzo-to (Tsumura TJ-68) on muscle cramps
accompanying cirrhosis in a placebo-controlled double-blind parallel study. <em>J Clin Ther
Med</em> 1999;15:499&#8211;523.</li>

<li class="Ref">Salmi HA, Sarna S. Effect of silymarin on chemical, functional and
morphological alterations of the liver. A double-blind controlled study. <em>Scand J
Gastroenterol</em> 1982;17:517&#8211;21.</li>

<li class="Ref">Feher J, Deak G, Muzes G, et al. Liver-protective action of silymarin therapy
in chronic alcoholic liver diseases. <em>Orv Hetil</em> 1989;130:2723&#8211;7 [in
Hungarian].</li>

<li class="Ref">Muzes G, Deak G, Lang I, et al. Effect of silymarin (Legalon) therapy on the
antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind
protocol.) <em>Orv Hetil</em> 1990:131:863&#8211;6 [in Hungarian].</li>

<li class="Ref">Velussi M, Cernigoi AM, De Monte A, et al. Long-term (12 months) treatment
with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need
and malondialdehyde levels in cirrhotic diabetic patients. <em>J Hepatol</em>
1997;26:871&#8211;9.</li>

<li class="Ref">Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of
silymarin treatment in patients with cirrhosis of the liver. <em>J Hepatol</em>
1989;9:105&#8211;13.</li>

<li class="Ref">Velussi M, Cernogoi AM, De Monte A, et al. Long-term (12 months) treatment
with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need
and malondialdehyde levels in cirrhotic diabetic patients. <em>J Hepatology</em>
1997;26:871&#8211;9.</li>

<li class="Ref">Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients
with cirrhosis of the liver: results of a double-blind, randomized and multicenter trial. <em>
J Hepatol</em> 1998;28:731&#8211;3.</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Liver_Cirrhosis.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:30:41 GMT -->
</html>

